Prostate cancer screening and its effect on disease-specific mortality has been a topic of debate since the early 1990s. In 2009, after publication of the results of two large randomized prostate cancer screening trials showing contradictory results, the debate continued. Meanwhile, based on the huge amount of data from these two trials it became clear there is no one-size-fits-all for prostate cancer screening. Now, with two recent publications, the debate on whether prostate cancer screening affects mortality can finally be ended. The focus is on how to identify those men that can benefit from screening.

Additional Metadata
Keywords Biopsy, Harm/benefit, Mortality, Over diagnosis, Prostate cancer, PSA, Screening
Persistent URL dx.doi.org/10.17925/OHR.2017.13.02.79, hdl.handle.net/1765/103444
Journal European Oncology and Haematology
Citation
Roobol-Bouts, M.J. (2017). Pearls for prostate cancer screening. European Oncology and Haematology, 13(2), 79–80. doi:10.17925/OHR.2017.13.02.79